Dr. Kennedy in this recent video brings up the interesting problem that he’s seeing which is that its very hard to predict how two “longevity therapeutics” interact and how widely varied the outcomes are.
He says in their lab that the outcomes they see are all over the map, and he cautions people to be careful in assuming that just because one drug or supplement has a positive effect, and another has a positive effect, combining the two together will also have a positive. In fact it can also have a negative or neutral effect (cancelling each other out). And of course the issues of combining more than two drugs or supplements are even more complex and difficult to predict.
How do you integrate this type of data into your own life and longevity strategy?
I tend to try to focus on drugs with the largest effects, and that seem to have largely discrete and differential pathways. My thinking is that these types of therapeutics are more likely to be additive in impact and less likely to be canceling each other out, or causing an “overdosing” of effect.
E.g Rapamycin - with its MTORC1 focus, and SGLT2 inhibitors which seems to work via blood glucose reductions (among other pathways that are still being determined). Similarly, this is why I’m very interested in 17-alpha estradiol, as it is yet another well differentiated pathway with significant longevity effects (at least in males).
And for supplements - I de-emphasize these because they don’t provide (in mouse studies) nearly the lifespan effects that these previously mentioned drugs do.
Here is the part of the interview with Brian Kennedy where he discusses their results of mixing multiple longevity therapeutics in their lab, and his recommendations of caution: